Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Pierre S. who wrote (1895)	5/17/1999 1:41:00 PM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

Pierre, I did mean the osteoarthritis market and thank you for the insights. I don't mean to put you on the spot; but, is it possible for you to share your own reaction to the opportunity to prescribe Pennsaid over other NSAIDS. I see you are a physician. I'd love to hear any thoughts you have on this. For instance would you see few or many applications? One more question if I may. How long would you expect a bottle of Pennsaid to last a patient? Thank you for helping me understand more about the product. I never thought about the types of applications you mentioned.

To: Pierre S. who wrote (1895)	5/17/1999 6:53:00 PM
From: DaveAu	Read Replies (1) \| Respond to of 14101

<< I see this market - even though it may not be indicated for this- as including sports and overuse injuries, which makes it at least double the size>> Pierre, Glad to hear you say that. Someone on this thread claimed the Edmonton Oilers were using Pennsaid at one time. It seemed plausible to me given that Glenn Sather is on the board of directors. This interests me because while we may not be able to get endorsements for a prescription product, the practices of professional athletes are well scrutinized by the press. The most recent example is an increase in the sales of a steroid product (I forget the name) when word got out that Mark McGuire uses it. BJ